×
About 23,233 results

ALLMedicine: Pneumonia Center

A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
https://www.nature.com/articles/s41392-020-0158-2

Corona Virus Disease 2019 (COVID-19) was first reported in late December 2019, in Wuhan, China. There are over 1,800,000 confirmed cases worldwide.1 The pathological process of severe COVID-19 pneumonia is an inflammation reaction characterized by the destruction of the deep airway and alveolar.2 It is currently considered that lung injury is not...

Effectiveness of methylprednisolone therapy in patients with a hig...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532093
Clinical and Experimental Medicine; Liu L, Qu H et. al.

Oct 23rd, 2021 - The optimal timing of glucocorticoid treatment for coronavirus disease 2019 (COVID-19) pneumonia is uncertain. We evaluated the clinical outcomes of methylprednisolone therapy (MPT) for patients with a high-risk common type (HRCT) COVID-19 pneumonia. We conducted a multicenter retrospective cohort study i...

Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia...
https://doi.org/10.1097/SHK.0000000000001574
Shock (Augusta, Ga.); Yuan M, Xu X et. al.

Jun 5th, 2020 - The effects of corticosteroid treatment on non-severe COVID-19 pneumonia patients are unknown. To determine the impacts of adjuvant corticosteroid administrated to patients with non-severe COVID-19 pneumonia. A retrospective cohort study based on propensity score analysis was designed to explore the effects of corticosteroid on several clinical outcomes...

Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280598
Journal of Medical Virology REFERENCES; Gong Y, Guan L et. al.

May 23rd, 2020 - The use of corticosteroids has been controversial in viral pneumonia. In most cases, application of methylprednisolone in severe and critical viral pneumonia patients can quickly alleviate the symptoms of dyspnea and prevent disease progression. However, some scholars have confirmed that corticosteroids delayed the body's clearance of the virus. In our retr...

Outcomes of tocilizumab therapy in severe or critical COVID-19...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662063
Tropical Medicine & International Health : TM & IH; Abdelnaby H, Aboelhassan W et. al.

Oct 4th, 2021 - To assess the effectiveness and safety of tocilizumab, a humanised anti-interleukin-6 receptor antibody, in the treatment of critical or severe coronavirus disease 2019 (COVID-19) patients. This was a retrospective cohort study of severe or critical COVID-19 patients (≥18 years) admitted to one hospital in Kuwait. Fifty-one patients received intravenous tocilizumab, while 78 patients received t...

Thrombosis in Covid-19 and non-Covid-19 pneumonia: r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204311
Platelets Violi F, Cammisotto V et. al.

Jun 8th, 2021 - Platelets may be a target of bacteria and viruses, which can directly or indirectly activate them so promoting thrombosis. In accordance with this, community-acquired pneumonia (CAP) is complicated by ischemia-related vascular disease (myocardial infarction and stroke) in roughly 10% of patients while the incidence of venous thrombosis is uncertain. In CAP platelet biosynthesis of TxA2 is augme...

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220898
The New England Journal of Medicine; Guimarães PO, Quirk D et. al.

Jun 17th, 2021 - The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hosp...

Bacterial infections and death among patients with Covid-19 versus non
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501886
The American Journal of Emergency Medicine; Scott H, Zahra A et. al.

Oct 13th, 2021 - Many patients with Coronavirus disease-2019 (Covid-19) present with radiological evidence of pneumonia. Because it is difficult to determine co-existence of bacterial pneumonia, many of these patients are initially treated with antibiotics. We compared the rates of bacterial infections and mortality in Covid-19 patients with pulmonary infiltrates...

Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for CO...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534629
American Journal of Respiratory and Critical Care Medicine; Pickens CO, Gao CA et. al.

Aug 20th, 2021 - Rationale: Current guidelines recommend patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia receive empirical antibiotics for suspected bacterial superinfection on the basis of weak evidence. Rates of ventilator-associated pneumonia (VAP) in clinical trials of patients with SARS-CoV-2 pneumonia are unexpectedly low. Objectives: We conducted an observational sing...

Microvascular Shunts in Covid-19 Pneumonia.
https://doi.org/10.1164/rccm.202111-2627LE
American Journal of Respiratory and Critical Care Medicine; Bush D, Abman SH et. al.

May 10th, 2022 - Microvascular Shunts in Covid-19 Pneumonia.|2022|Bush D,Abman SH,Galambos C,|

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953459
The New England Journal of Medicine; Rosas IO, Bräu N et. al.

Feb 26th, 2021 - Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort stu...

The Lungs Before and After COVID-19 Pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356438
The American Journal of Tropical Medicine and Hygiene; Orsi MA, Oliva G et. al.

May 16th, 2020 - The Lungs Before and After COVID-19 Pneumonia.|2020|Orsi MA,Oliva G,Cellina M,|diagnostic imaging,pathology,diagnostic imaging,pathology,virology,diagnostic imaging,pathology,

The Bronchial Circulation in COVID-19 Pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865596
American Journal of Respiratory and Critical Care Medicine; Ackermann M, Tafforeau P et. al.

Nov 5th, 2021 - The Bronchial Circulation in COVID-19 Pneumonia.|2021|Ackermann M,Tafforeau P,Wagner WL,Walsh CL,Werlein C,|pathology,pathology,blood,blood supply,blood,

COVID-19 pneumonia: pathophysiology and management.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527244
European Respiratory Review : an Official Journal of the ... Gattinoni L, Gattarello S et. al.

Oct 22nd, 2021 - Coronavirus disease 2019 (COVID-19) pneumonia is an evolving disease. We will focus on the development of its pathophysiologic characteristics over time, and how these time-related changes determine modifications in treatment. In the emergency department: the peculiar characteristic is the coexistence, in a significant fraction of patients, of severe hypoxaemia, near...

Organizing pneumonia-like pattern in COVID-19.
https://doi.org/10.5603/ARM.a2021.0081
Advances in Respiratory Medicine; Raoufi M, Kahkooei S et. al.

Oct 7th, 2021 - Organizing pneumonia (OP) is a radio-histologic pattern that forms in response to lung damage in patients with focal or diffuse lung injury. OP is frequently observed subsequent to viral-induced lung damage and is associated with a diverse range of clinical outcomes. We included 210 patients (mean age: 55.8 ± 16.5 years old; 61% male) with mild Coronavirus disease 2019 (COVID...

Racial/ethnic disparities on inflammation and response to methylprednisolone in severe ...
https://doi.org/10.1186/s12879-022-07237-1 10.1016/j/mehy.2020.110220 10.1186/s12879-021-05945-8 10.3389/fimmu.2021.613422 10.1002/jmv.26097 10.1136/jclinpath-2021-207446 10.1097/CCE.0000000000000493 10.1097/01.hjh.0000752564.68879.af 10.1007/s00134-020-06026-1 10.1016/j.kint.2020.04.003 10.1186/s13613-021-00875-9 10.1001/jamanetworkopen.2021.4117 10.3390/nu13020 10.1155/2021/9947370 10.1016/S2213-2600(21)00331-3
BMC Infectious Diseases; Go RC, Nyirenda T et. al.

Mar 16th, 2022 - Racial/ethnic minorities are at higher risk for severe COVID-19. This may be related to social determinants that lead to chronic inflammatory states. The aims of the study were to determine if there are racial/ethnic disparities with inflammatory markers and association of methylprednisolone to in hospital survival. This was a secondary analysis of a retros...

Cytokine storm in severe COVID-19 pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242613
Journal of Medical Virology; Gürsoy B, Sürmeli CD et. al.

May 9th, 2021 - In this study, laboratorial parameters of hospitalized novel coronavirus (COVID-19) patients, who were complicated with severe pneumonia, were compared with the findings of cytokine storm developing in macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH). Severe pneumonia occurred as a result of cytokine storm ...

Quantitative CT comparison between COVID-19 and mycoplasma pneumonia...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818096
BMC Medical Imaging; Liu J, Wang Y et. al.

Feb 8th, 2022 - The purpose of this study was to compare imaging features between COVID-19 and mycoplasma pneumonia (MP). The data of patients with mild COVID-19 and MP who underwent chest computed tomography (CT) examination from February 1, 2020 to April 17, 2020 were retrospectively analyzed. The Pneumonia-CT-LKM-PP model based on a deep learning algorithm was used ...

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
https://doi.org/10.1056/NEJMoa2030340
The New England Journal of Medicine; Salama C, Han J et. al.

Dec 18th, 2020 - Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti-interleukin-6 receptor antibody tocilizumab in patients from these populations who are hospitalized with Covid...

Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148307
PloS One; Pinzón MA, Ortiz S et. al.

May 26th, 2021 - There is no effective therapy for the severe acute respiratory syndrome by coronavirus 2 (SARS-CoV2) responsible for the Coronavirus disease 2019 (Covid-19). To date, dexamethasone has shown a decrease in mortality in patients who require oxygen, especially those with invasive mechanical ventilation. However, it is unknown if another corticosteroid can ...